Nordic Nanovector’s Scientific Advisory Board (SAB) members are internationally recognized researchers. Their collective expertise complements the focus of our product development efforts. Scientific Advisory Board member responsibilities include the critical review of our product development programs and advising the Management and the Board of Directors on our technical efforts.
Prof. Timothy Martin Illidge (UK): is professor of Targeted Therapy and Oncology and Honorary Consultant in Oncology , University of Manchester and Christie NHS Trust. He holds a BSc. Biochemistry from the London University and M.B:, B.S. from Guy’s Hospital , London. He is member of the Royal College of Physicians, Fellow of Royal College of radiologists and Fellow of Royal College of Pathologists. He was awarded a Ph.D. from Southampton University for this work in the field of radioimmunotherapy of lymphomas. He holds numerous research scholarships and fellowships, and have received several research council grants and prestigious research awards, amongst other “Research of the year” from the Institute of Cancer Sciences, University of Manchester and “Researcher of the year” from the Faculty of Human and Life Sciences University of Manchester. He has several leaderships in cancer research , amongst others Chairman NCRI Clinical and Translational Radiotherapy Group (CTRad) since 2010, he is currently chair of the radiotherapy related research group of the Manchester Cancer research Centre and Deputi Director of the Institute of Cancer Sciences, University of Manchester.
Prof. Pierluigi Zinzani (Italy): Prof Zinzani is Associate Professor of Hematology at the Institute of Hematology “L. e A. Seràgnoli” at the University of Bologna. He is a member of the Italian Society of Hematology, the Italian Society of Experimental Hematology, the American Society of Hematology and American Society of Clinical Oncology and has presented his research at more than 220 national and international meetings. He has written more than 400 refereed articles in journals such as Blood, the Journal of Clinical Oncology, Lancet Oncology, Haematologica and Annals of Oncology. His current research interest includes clinical trial methodology, prognostic factors in NHL, Hodgkin’s disease, chronic lymphocytic leukemia, new drugs development, and hairy cell leukemia. He is President of FIL (Italian Lymphomas Federation) since November 2013 and Associate Editor of Annals of Oncology since January 2014.
Dr. Arne Kolstad (Norway): Arne Kolstad is senior consultant in medical oncology and radiotherapy at Oslo University Hospital Radiumhospitalet and also holds a research position funded by the Norwegian Cancer Society. He is chairman of the Norwegian Lymphoma Group and leader of Oslo University Hospital focus area Cancer Immunotherapy. His man scientific interests are radioimmunotherapy, cellular therapies and cancer vaccines in malignant lymphoma. He published two papers as first author in Blood 2014, one as principal investigator of Nordic trial on radioimmunotherapy in mantle cell lymphoma and another as principal investigator of a cancer vaccine trial in follicular lymphoma. He has been visiting scientist at University of Michigan in Mark Kaminskis group in 1998/99 and visiting professor at Stanford University in Ron Levys group inn 2007/8. He has published more than 60 original papers in international journals and was awarded Ragnar Mørks prize for cancer research at Oslo University Hospital Radiumhospitalet in 2014. He also was awarded a prize for best original article at Oslo University Hospital in 2014.
Prof. Dolores Caballero (Spain): Professor Caballero is the Head of Clinic and Transplant Unit at the University Hospital in Salamanca (Spain ); her unit performs 80-90 transplant per year; she is also assistant professor of medicine (hematology) at the University of Salamanca (Spain) and the President of the Spanish cooperative group in transplant in lymphomas (GELTAMO). She has authored over 200 scientific papers in international journals and 15 chapters of books and conducted over 40 clinical trials In lymphomas.in 2014.
Prof. Stephen Schuster is the Robert and Margarita Louis-Dreyfus Associate Professor of Chronic Lymphocytic Leukemia and Lymphoma, Associate Professor of Medicine, and Associate Professor of Radiation Oncology at the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania. He also serves as Director of the Lymphoma Program and Director of Lymphoma Translational Research at the Abramson Cancer Center of the University of Pennsylvania.
After graduating from Jefferson Medical College and completing a residency in Internal Medicine at Pennsylvania Hospital, Dr. Schuster went on to clinical and research fellowships at the Cardeza Foundation for Hematologic Research. In 1989, he became a member of the Cardeza Foundation and joined the faculty at Jefferson Medical College. He joined the Hematologic Malignancy Department at the University of Pennsylvania in 1998. Since that time, his research has focused on the development and application of novel immunotherapies for non-Hodgkin lymphomas and chronic lymphocytic leukemia, including use of autologous tumor-derived vaccines, autologous co-stimulated T-cells for immune reconstitution after chemotherapy, radioimmunotherapy, and monoclonal antibody therapy. Dr. Schuster is a recipient of the deVilliers Society Award for outstanding support to the cause of fighting blood-related cancers and improving the quality of life for patients and their families, the Research Recognition Award, the Hope Award for Medical Achievement from the Leukemia and Lymphoma Society, and the Ehrenzeller Award from Pennsylvania Hospital. He has also received numerous awards for outstanding teaching and research from both Jefferson Medical College and the University of Pennsylvania.
Prof. Armando Lopez-Guillermo (Spain): is a senior consultant at the Department of Hematology in Hospital Clinic, Barcelona, Spain. His main lines of research include follicular, mantle-cell, diffuse large B-cell and peripheral T-cell lymphomas and chronic lymphocytic leukemia.
He has participated in several international groups such as IELSG, IFLIPP, F2. Dr. López-Guillermo has also collaborated in the study of the genomic profile of the diffuse large cell lymphoma and its clinical significance in collaboration with the National Cancer Institute (U.S.A.) and the Leukemia Lymphoma Molecular Profiling Project (LLMPP). He is the chairman of Scientific Committee in GELTAMO cooperative group (Spanish group of lymphomas) and he has over 200 published papers.
Prof. Francesco D’Amore (Denmark) received his MD from the University of Genoa, Italy in 1980. He was a Resident at Genoa University from 1980 to 1982. He worked as a Research Fellow in the Department of Haematology and Pathology at the University of Odense, Denmark from 1990 to 1994.
Following completion of a Post-Doctoral Research Associate position at the University of Nebraska Medical Center, Omaha, USA, Dr d'Amore returned to Denmark in 1996, where he was appointed the position of Senior Registrar at Aarhus University Hospital, Denmark. Since 1999, he has held, at the same institution, the position of Consultant Haematologist responsible for the lymphoma unit.
Since January 2010, he was appointed clinical professor in malignant lymphoproliferative diseases at the Dept. of Hematology, Aarhus University Hospital. Dr d'Amore's research interests include non-Hodgkin's lymphoma with particular focus on T-cell lymphomas as well as Hodgkin lymphoma. He is currently Chairman of the Working Group on T-cell lymphomas of the Nordic Lymphoma Group. He is a member of the Coordinating Committee of The Nordic Lymphoma Group.
Prof. Mark Kaminski (US) is professor of Hematology/Oncology, University of Michigan. His clinical focus is treatment of lymphomas (Hodgkin’s and non-Hodgkin’s), and leukemia, with a special emphasis on cancer immunology and therapies based in monoclonal antibodies, biologic response modifiers, and radioimmunoconjugates. He is currently director of the leukemia/lymphoma program and the Michigan University Comprehensive Cancer Center and head of the Multidisciplinary Lymphoma Clinic. He earned a M.D. from Stanford University in 1978, did his internal medicine residency training at Barnes Hospital /Washington University of St. Louis, and was a post-doctoral fellow in medical oncology at Stanford from 1981 to 1985.
Prof. Wojciech Jurczak (Poland) is a consultant and professor of hematology at Jagiellonian University, Cracow, Poland where he leads the lymphoma team since 1992. Most of the his research activity in the first 15 years were related to development of monoclonal antibodies in B cell lymphomas, and practical aspects of stem cell transplantation. At that time radio-immunotherapy with Y90 labeled Ibritumomab tiuxetan was investigated, especially as consolidation of MCL and DLBCL patients, either in mono-therapy, or as an element of Z-BEAM conditioned ASCT. In the last decade, establishing MCM, a private research facility, allowed the lymphoma team to take part in over 50 clinical trials, including registration studies for Ibrutinib, Idelalisib, Belinostat, Lenalidomide, ABT199 and Rituximab biosymilars. Being a member of ASH, ASCO, PLRG and EMCLN, he co-authored papers published in NEJM, Blood, JCO, Lancet Oncology, Annals of Oncology etc.al oncology at Stanford from 1981 to 1985.
Prof. Lorenz Trümper (Germany): Prof. Trümper is the Director and Chairman of the Department of Hematology and Oncology at the Göttingen Comprehensive Cancer Center and Professor of Hematology and Oncology at the University of Göttingen . His research interests focus on molecular mechanisms of lymphomagenesis, mechanisms of invasion and metastasis, clinical research in malignant lymphoma and stem cell transplantation. He is a reviewer of several scientific journals , including Blood, Cancer Research, Leukemia, International Journal of Cancer and Annals of Hematology.Stanford from 1981 to 1985.
Prof. Morschhauser (France): Franck Morschhauser is a Professor of Hematology and Head of the Lymphoma Unit in the Department of Hematology at the Centre Hospitalier Universitaire de Lille, in Lille, France. He is a graduate of the University of Lille, where he received his Medical degree. Dr Morschhauser serves on the Administration and Scientific Boards for LYSA (Lymphoma Study Association). Dr Morschhauser’s research interests focus on new drug development, targeted therapy, and predictive quantitative imaging for the treatment of lymphoma. He has a strong focus on translational research. He has been involved in many clinical trials. Dr Morschhauser has contributed to 118 articles published in peer reviewed journals.